Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012 On August 13, 2012

Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the fourth quarter and full year of fiscal 2012 on Monday, August 13, 2012, and will hold a conference call on Tuesday, August 14, 2012 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Conference Call Information

Date:
  Tuesday, August 14, 2012

Time:
9:00 a.m. eastern time

Toll-Free:
800 561.2718

Toll:
617 614.3525

Pass Code:
62242246

Webcast & Conference Call Slides:

http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome
 

A replay of the call will be available as a webcast on www.arraybiopharma.com.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.

Copyright Business Wire 2010

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX